This page cannot be printed from here

Please use the dedicated print option from the 'view' drop down menu located in the blue ribbon in the top, right section of the publication.

screenshot of print menu option

Description: Pharmaceutical Industry Wastewater Treatment Using MABR
Pharmaceutical Industry Wastewater Treatment Using MABR
Abstract
Teva, a global pharmaceuticals company, was exploring alternatives for improving TN removal in its treatment plants. MABR was selected for onsite lab testing with real wastewater. Results show that nitrificatin rate is lower than for municipal wastewater but sufficient for the plant, and that simultaneous nitrification and denitrification can be obtained to achieve the TN removal goals. Optimal C/N for SND was determined experimentally, and NGS was used to characterize the abundance of nitrifying bacteria in the MABR compared to the existing process.
The following conference paper was presented at WEFTEC 2021, October 16-20, 2021. To read the full abstract, see "Abstract" tab below.
SpeakerShechter, Ronen
Presentation time
11:40:00
11:50:00
Session time
11:00:00
12:30:00
SessionKnowledge Development Forum: Bioaugmentation - 2 Perspectives and Aerobic Membrane Advances Applied
Session number417
TopicIndustrial Issues and Treatment Technologies, Research and Innovation
TopicIndustrial Issues and Treatment Technologies, Research and Innovation
Author(s)
Ronen Shechter
Author(s)R. Shechter1; L. Farkash2; G. Bartal2;
Author affiliation(s)Fluence, IS1Teva Pharmaceutical Industries, IS2
SourceProceedings of the Water Environment Federation
Document typeConference Paper
PublisherWater Environment Federation
Print publication date Oct 2021
DOI10.2175/193864718825158116
Volume / Issue
Content sourceWEFTEC
Copyright2021
Word count7

Purchase price $11.50

Get access